Dexcom revenue

Dexcom's revenue was $4.66bn in fiscal 2025, up 15.6% on the year before. Since fiscal 2009 ($29.7m) it has grown at a compound 37.2% a year. Over the last twelve months it was $5.10bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Dexcom: revenue history, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	30	49	76	100	160	259	402	573	719	1,032	1,476	1,927	2,449	2,910	3,622	4,033	4,662	5,104
Growth on the year before	—	+63.7%	+57.0%	+30.9%	+60.2%	+62.0%	+55.1%	+42.6%	+25.3%	+43.6%	+43.1%	+30.5%	+27.1%	+18.8%	+24.5%	+11.3%	+15.6%	—
Gross profit	4	18	36	47	100	176	278	378	492	664	932	1,280	1,681	1,883	2,289	2,438	2,802	3,237
Gross margin	12.3%	37.9%	47.1%	46.6%	62.6%	68.0%	69.3%	66.0%	68.5%	64.4%	63.1%	66.4%	68.6%	64.7%	63.2%	60.5%	60.1%	63.4%

US$ millions unless shown otherwise. Fiscal quarters.

Dexcom: revenue history, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	1,114	1,036	1,157	1,209	1,260	1,192	1,308	1,345
Growth on the same quarter a year before	—	—	—	—	+13.1%	+15.0%	+13.1%	+11.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025

Geography
Region	Revenue	Share	YoY
United States	$3.3B	71.5%	▲ 15.4%
Outside the US	$1.3B	28.5%	▲ 16.1%

From Dexcom's 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Dexcom	$5.10bn	13.0%	14.5%
Bausch & Lomb Corp	$5.42bn	8.9%	10.9%
Idexx Laboratories	$4.66bn	11.9%	9.1%
ResMed\|	$5.73bn	9.0%	9.4%
Steris	$6.04bn	8.4%	9.0%
Edwards Lifesciences	$6.51bn	14.6%	15.3%

Compare with peers

Head to head: BLCO vs DXCM DXCM vs IDXX DXCM vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Dexcom's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dexcom.